Outset Medical, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Outset Medical, Inc. on June 4, 2026. The meeting was conducted virtually via live audio webcast. As of the record date of April 9, 2026, there were 18,529,233 shares of common stock outstanding entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting results.
Material Changes and Voting Results
Three proposals were acted upon by stockholders, with a quorum of 13,890,864 shares present:
- Proposal One (Election of Class III Directors): Brent D. Lang and Karen Prange were elected to serve until the 2029 annual meeting.
- Brent D. Lang: 8,109,357 For; 2,642,698 Withheld.
- Karen Prange: 10,317,822 For; 434,233 Withheld.
- Proposal Two (Advisory Vote on Executive Compensation): The 2025 compensation of named executive officers was approved.
- For: 7,548,774; Against: 3,196,870; Abstain: 6,411.
- Proposal Three (Ratification of Auditors): KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- For: 13,554,287; Against: 20,047; Abstain: 316,530.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new Class III directors' terms extending to 2029.
- The significant number of votes cast against the executive compensation proposal (3,196,870 against vs. 7,548,774 for).
- Verification of KPMG LLP's appointment for the 2026 fiscal year.
- Review of the 2026 proxy statement for details on the executive compensation package that received a substantial "against" vote.